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Objective. The 1980 American College of Rheuma-
tology (ACR) classification criteria for systemic sclero-
sis (SSc) lack sensitivity for early SSc and limited
cutaneous SSc. The present work, by a joint committee
of the ACR and the European League Against Rheuma-
tism (EULAR), was undertaken for the purpose of
developing new classification criteria for SSc.
Methods. Using consensus methods, 23 candidate
items were arranged in a multicriteria additive point
system with a threshold to classify cases as SSc. The
classification system was reduced by clustering items
and simplifying weights. The system was tested by
1) determining specificity and sensitivity in SSc cases
and controls with scleroderma-like disorders, and
2) validating against the combined view of a group of
experts on a set of cases with or without SSc.
Results. It was determined that skin thickening of
the fingers extending proximal to the metacarpopha-
langeal joints is sufficient for the patient to be classified
as having SSc; if that is not present, 7 additive items
apply, with varying weights for each: skin thickening of
the fingers, fingertip lesions, telangiectasia, abnormal
nailfold capillaries, interstitial lung disease or pulmo-
nary arterial hypertension, Raynaud’s phenomenon,
and SSc-related autoantibodies. Sensitivity and speci-
ficity in the validation sample were, respectively, 0.91
and 0.92 for the new classification criteria and 0.75 and
0.72 for the 1980 ACR classification criteria. All selected
cases were classified in accordance with consensus-
based expert opinion. All cases classified as SSc accord-
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ing to the 1980 ACR criteria were classified as SSc with
the new criteria, and several additional cases were now
considered to be SSc.
Conclusion. The ACR/EULAR classification crite-
ria for SSc performed better than the 1980 ACR criteria
for SSc and should allow for more patients to be
classified correctly as having the disease.
Introduction
Systemic sclerosis (SSc; scleroderma) is a hetero-
geneous disease whose pathogenesis is characterized by
3 hallmarks: small vessel vasculopathy, production of
autoantibodies, and fibroblast dysfunction leading to
increased deposition of extracellular matrix (1). The
clinical manifestations and the prognosis of SSc vary,
with the majority of patients having skin thickening and
variable involvement of internal organs. Subsets of SSc
can be discerned, i.e., limited cutaneous SSc, diffuse
cutaneous SSc, and SSc without skin involvement (1).
In the absence of a diagnostic test proving the
absence or presence of SSc, several sets of classification
criteria have been developed (2–6). The purpose of
classification criteria is to enroll, in research studies,
patients who in fact have the disease as determined
using a uniform definition (7). Classification criteria are
not synonymous with diagnostic criteria but will almost
always mirror the list of criteria that are used for
diagnosis (7). However, classification criteria generally
are more standardized and less inclusive than physician
diagnosis.
The current standard classification criteria for
SSc are the 1980 preliminary criteria for the classifica-
tion of systemic sclerosis (scleroderma), developed by
the American College of Rheumatology (ACR) (2–4,8).
These classification criteria were developed using pa-
tients with longstanding SSc. As a consequence, patients
with early SSc and 20% of patients with limited
cutaneous disease do not meet the criteria and are
excluded from clinical studies (1,9,10). Since the devel-
opment of the 1980 criteria, knowledge regarding SSc-
related autoantibodies has improved (11–13). In addi-
tion, characteristic nailfold capillary changes have been
found to be associated with SSc, and nailfold capillaros-
copy is widely accepted as a diagnostic tool (10,14–17).
In 1988, LeRoy et al proposed new criteria that included
clinical features, autoantibodies, and capillaroscopy re-
sults, highlighting the differences between the 2 main
SSc subsets (11). In 2001, LeRoy and Medsger proposed
to revise the classification criteria to include “early”
SSc, using nailfold capillary pattern and SSc-related
autoantibodies (6). It also has been demonstrated that
the addition of nailfold capillary abnormalities and
telangiectasias to the ACR SSc criteria improves their
sensitivity (9,18).
Because of the insufficient sensitivity of the
1980 criteria and advances in knowledge about SSc, the
ACR and the European League Against Rheumatism
(EULAR) established a committee to provide a joint
proposal for new classification criteria for SSc. The aims
were to develop criteria that 1) encompass a broader
spectrum of SSc including patients whose disease is
in the early stage as well as those in the late stage;
2) include vascular, immunologic, and fibrotic manifes-
tations; 3) are feasible to use in daily clinical practice;
and 4) are in accordance with criteria used for diagnosis
of SSc in clinical practice (7). These criteria are intended
to be used by rheumatologists, researchers, national and
international drug agencies, pharmaceutical companies,
or any others involved in studies of SSc. Our objective
was to develop a set of criteria that would enable
identification of individuals with SSc for inclusion in
clinical studies, being more sensitive and specific than
previous criteria.
Methods
Overview. The development and testing of the classifi-
cation system for SSc was based on both data and expert
clinical judgment. First, candidate items for the classification
criteria were generated using consensus methods and evalu-
ated using existing databases (19,20). Second, multicriteria
decision analysis was used to reduce the number of candidate
criteria and assign preliminary weights (21). The classification
system was repeatedly tested and adapted using prospectively
collected SSc cases and non-SSc controls, and compared
against expert clinical judgment. Third, the classification crite-
ria were tested in a validation cohort and tested against
preexisting criteria sets.
Item generation and reduction. One hundred sixty-
eight candidate criteria were identified through 2 Delphi
exercises. A 3-round Delphi exercise and a face-to-face con-
sensus meeting using nominal group technique facilitated
reduction of the 168 items to 23 (19). Using a random sample
of existing databases (SSc [n  783] and control patients with
diseases similar to SSc [n  1,071], all based on physician
diagnosis), the candidate criteria were found to have good
discriminative validity (20).
Item reduction and weighting. Draft classification sys-
tem. A face-to-face meeting of 4 European and 4 North
American SSc experts was held to further reduce items and
assign preliminary weights using multicriteria decision analysis.
The number of experts was limited in advance to 8, and they
were invited based on geographic representation, knowledge
from a scientific and a practical diagnostic viewpoint, and
availability. At the meeting, the experts determined by consen-
sus to which cases the criteria should be and should not be
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applied, and which items are sufficient to allow classification of
a patient as having SSc (sufficient criteria). They then partic-
ipated in a multicriteria decision analysis to further reduce the
23 items and assign preliminary weights (21). The experts were
presented hypothetical pairs of cases with 2 of the 23 items at
a time (e.g., Raynaud’s phenomenon positive and abnormal
nailfold capillaries absent versus Raynaud’s phenomenon neg-
ative and abnormal nailfold capillaries present, all other man-
ifestations being considered equal) and they were asked to
individually vote electronically on which case of the pair was
more likely to be SSc. The result of the votes was immediately
presented. If there was no complete agreement among the
experts, considerations were discussed and a second round of
voting was conducted. As a result of the repeated choices
between 2 alternative cases, items were ranked, and weights for
the items were derived using 1000Minds decision-making
software (21). Additional details about the methods are avail-
able in ref. 22.
Initial threshold identification. The committee prepared
summaries of 45 SSc cases, with a concentration of cases that
were difficult to classify. These were presented to 22 SSc
experts who classified the cases as definite SSc or not. The
draft classification system derived from the multicriteria deci-
sion analysis was applied to the 45 cases, resulting in a score for
each case. The ranking of cases by the SSc experts and the
ranking of cases based on the scores provided with the draft
scoring system were examined. Higher scores in the scoring
system were expected to relate to a higher probability that the
experts would classify the case as SSc. Using these results, an
initial threshold score for SSc was identified.
Reduction and testing of iterative changes. In the next
step, the committee reduced the number of items, simplified
the weights, and modified the threshold score. First, data on
the candidate items were prospectively collected at 13 SSc
centers in North America and 10 in Europe, using standard-
ized case record forms. Data from 368 consecutive patients
with SSc (diagnosis based on physician opinion) were col-
lected, of whom half were to have had SSc for a maximum of
2 years (based on the time from the first non-Raynaud’s
symptom) in order to include early SSc. Data from 237
consecutive control patients with a scleroderma-like disorder
(eosinophilic fasciitis [also called Shulman’s disease or diffuse
fasciitis with eosinophilia], scleromyxedema, systemic lupus
erythematosus, dermatomyositis, polymyositis, primary Ray-
naud’s phenomenon, mixed connective tissue disease, undif-
ferentiated connective tissue disease, generalized morphea,
nephrogenic systemic sclerosis, and diabetic cheiroarthropa-
thy) were also collected. From these 605 patients a random
sample of 100 SSc cases and 100 controls (50% from North
America and 50% from Europe) was selected to form the
derivation sample. The remaining 268 cases and 137 controls
formed the validation sample. Institutional research ethics
board approval was obtained for the collection of patient data.
The committee then met and made iterative changes to
the draft system, which they continually applied in real time to
the derivation cohort derived as described above. Using the
derivation cohort, the scoring system was simplified by remov-
ing items that occurred with low frequency or were redundant,
by aggregating similar items and then transforming the weights
to obtain single digits. The preliminary score threshold was
adjusted to account for the weight simplification. The impact
of all proposed changes was evaluated by assessing changes
to sensitivity and specificity of the criteria in the derivation
cohort. The reference standard to test the sensitivity and
specificity was the diagnosis by the SSc expert who submitted
the case(s) and control(s).
At the same time, the changes in the classification
system were also tested in 38 difficult-to-classify cases. Conse-
quently, weights of some items were adjusted to align the
scoring system with the reference standard formed by the
opinions of the SSc experts as to which cases were to be
classified as having SSc.
Validation. The final classification system was indepen-
dently tested using the validation sample of SSc cases and
controls. Sensitivity and specificity were calculated for the 1980
ACR preliminary classification criteria for SSc (3), the classi-
fication criteria proposed by LeRoy and Medsger in 2001 (6),
and the newly developed classification criteria. Exact binomial
confidence limits were calculated for sensitivity and specificity.
The ACR criteria and LeRoy/Medsger criteria were com-
pared with the new criteria using 2  2 tables with McNemar’s
chi-square test and continuity correction. The criteria sets were
also tested separately using only the subgroup of patients with
a disease duration of 3 years. Further, the classification
system was validated against the expert consensus on the set of
38 selected cases.
Results
Draft classification system. The experts con-
cluded that “skin thickening of the fingers of both hands
extending proximal to the metacarpophalangeal joints”
was sufficient to classify a subject as having SSc. Further,
patients with “skin thickening sparing the fingers” are
classified as not having SSc. It was agreed that the
criteria should be applied to any patient considered for
inclusion in an SSc study, without further specifications.
Items with relatively low weights were deleted, and items
considered to be from a similar domain were clustered
(e.g., fingertip lesions encompasses ulcers and pitting
scars; lung involvement encompasses interstitial lung
disease and pulmonary hypertension). Using conjoint
analysis, the number of items was reduced from 23 to 14
and all items were assigned weights. The 14 resulting
items (with weights) were as follows: bilateral skin
thickening of the fingers (sclerodactyly) (weighted 14 if
distal to a proximal interphalangeal joint only, 22 if
whole finger), puffy fingers (weighted 5), fingertip le-
sions (weighted 16 if pitting scars or 9 if digital ulcers),
finger flexion contractures (weighted 16), telangiectasia
(weighted 10), abnormal nailfold capillaries (weighted
10), calcinosis (weighted 12), Raynaud’s phenomenon
(weighted 13), tendon or bursal friction rubs (weighted
21), interstitial lung disease/pulmonary fibrosis
(weighted 14), pulmonary arterial hypertension
(weighted 12), scleroderma renal crisis (weighted 11),
esophageal dilation (weighted 7), and SSc-related auto-
antibodies (weighted 15 if anticentromere antibody pres-
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Table 1. The American College of Rheumatology/European League Against Rheumatism criteria for the classification of systemic sclerosis (SSc)*
Item Sub-item(s) Weight/score†
Skin thickening of the fingers of both hands extending proximal
to the metacarpophalangeal joints (sufficient criterion)
– 9
Skin thickening of the fingers (only count the higher score) Puffy fingers 2
Sclerodactyly of the fingers (distal to the
metacarpophalangeal joints but
proximal to the proximal
interphalangeal joints)
4
Fingertip lesions (only count the higher score) Digital tip ulcers 2
Fingertip pitting scars 3
Telangiectasia – 2
Abnormal nailfold capillaries – 2
Pulmonary arterial hypertension and/or interstitial lung disease
(maximum score is 2)
Pulmonary arterial hypertension 2
Interstitial lung disease 2
Raynaud’s phenomenon – 3
SSc-related autoantibodies (anticentromere,
anti–topoisomerase I [anti–Scl-70], anti–RNA
polymerase III) (maximum score is 3)
Anticentromere 3
Anti–topoisomerase I
Anti–RNA polymerase III
* These criteria are applicable to any patient considered for inclusion in an SSc study. The criteria are not applicable to patients with skin thickening
sparing the fingers or to patients who have a scleroderma-like disorder that better explains their manifestations (e.g., nephrogenic sclerosing fibrosis,
generalized morphea, eosinophilic fasciitis, scleredema diabeticorum, scleromyxedema, erythromyalgia, porphyria, lichen sclerosis, graft-versus-host
disease, diabetic cheiroarthropathy).
† The total score is determined by adding the maximum weight (score) in each category. Patients with a total score of 9 are classified as having
definite SSc.
Table 2. Definitions of items/sub-items in the American College of Rheumatology/European League Against Rheumatism criteria for the
classification of systemic sclerosis (SSc)
Item Definition
Skin thickening Skin thickening or hardening not due to scarring after injury, trauma, etc.
Puffy fingers Swollen digits—a diffuse, usually nonpitting increase in soft tissue mass of the digits extending
beyond the normal confines of the joint capsule. Normal digits are tapered distally with the tissues
following the contours of the digital bone and joint structures. Swelling of the digits obliterates
these contours. Not due to other causes such as inflammatory dactylitis.
Fingertip ulcers or pitting scars Ulcers or scars distal to or at the proximal interphalangeal joint not thought to be due to trauma.
Digital pitting scars are depressed areas at digital tips as a result of ischemia, rather than trauma
or exogenous causes.
Telangiectasia Telangiectasiae are visible macular dilated superficial blood vessels, which collapse upon pressure
and fill slowly when pressure is released. Telangiectasiae in a scleroderma-like pattern are round
and well demarcated and found on hands, lips, inside of the mouth, and/or are large mat-like
telangiectasiae. Distinguishable from rapidly filling spider angiomas with central arteriole and from
dilated superficial vessels.
Abnormal nailfold capillary pattern
consistent with systemic sclerosis
Enlarged capillaries and/or capillary loss with or without pericapillary hemorrhages at the nailfold.
May also be seen on the cuticle.
Pulmonary arterial hypertension Pulmonary arterial hypertension diagnosed by right-sided heart catheterization according to standard
definitions.
Interstitial lung disease Pulmonary fibrosis seen on high-resolution computed tomography or chest radiography, most
pronounced in the basilar portions of the lungs, or occurrence of “Velcro” crackles on
auscultation, not due to another cause such as congestive heart failure.
Raynaud’s phenomenon Self-reported or reported by a physician, with at least a 2-phase color change in finger(s) and often
toe(s) consisting of pallor, cyanosis, and/or reactive hyperemia in response to cold exposure or
emotion; usually one phase is pallor.
SSc-related autoantibodies Anticentromere antibody or centromere pattern seen on antinuclear antibody testing, anti–
topoisomerase I antibody (also known as anti–Scl-70 antibody), or anti–RNA polymerase III
antibody. Positive according to local laboratory standards.
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ent, anticentromere pattern seen on antinuclear anti-
body testing, or anti–topoisomerase I [also called anti–
Scl-70] or anti–RNA polymerase III present).
Initial threshold identification. Comparison of
the case ranking from the scoring system and by the
experts revealed that most of the experts (75%) con-
sidered the cases with a score of 55 (except for 1 case)
to be SSc. Similarly, most experts (88%) considered
cases with a score of 40 not to be SSc. With scores
between 40 and 55 there was more diversity of opinion.
Thus, it was concluded that the initial threshold would
be a score of 56.
Reduction and testing of iterative changes. The
14 items in the scoring system were reduced to 9 while
Table 3. Characteristics of the derivation sample and the validation sample*
Item
Derivation sample Validation sample
SSc
(n  100)
Scleroderma-
like disorder
(n  100) P
SSc
(n  268)
Scleroderma-
like disorder
(n  137) P
Age, mean  SD years 55  13 51  15 0.05 54 13 52 15 0.17
Female 86 (86) 79 (79) 0.25 221 (83) 101 (75) 0.08
Region
North America 50 50 – 191 (68) 91 (32) –
Europe 50 50 77 (63) 46 (37) 0.32
Time since onset of Raynaud’s phenomenon,
median (IQR) years
13 (7–18) 12 (4–18) 0.42 9 (5–18) 10 (4–22) 0.40
Time since first non-Raynaud’s symptom,
median (IQR) years
10 (4–13) 9 (2–14) 0.58 7 (3–12) 7 (3–15) 0.89
Time since diagnosis, median (IQR) years 8 (3–12) 6 (1–9) 0.10 5 (2–11) 4 (1–7) 0.016
Scleroderma-like disorders
Systemic lupus erythematosus – 28 (28) – – 32 (23) –
Polymyositis/dermatomyositis – 23 (23) – – 21 (15) –
Primary Raynaud’s phenomenon – 19 (19) – – 7 (5) –
Mixed connective tissue disease – 9 (9) – – 14 (10) –
Undifferentiated connective tissue disease – 8 (8) – – 17 (12) –
Eosinophilic fasciitis – 6 (6) – – 16 (12) –
Nephrogenic sclerosing fibrosis – 3 (3) – – 3 (2) –
Generalized morphea – 5 (5) – – 8 (6) –
Scleromyxedema – 1 (1) – – 3 (2) –
Graft-versus-host disease – 3 (3) – – 3 (2) –
Other diagnoses – 8 (8) – – 13 (9) –
Manifestations† – – – – – –
Raynaud’s phenomenon 91 (91) 49 (49) 0.0001 257 (96) 63 (46) 0.0001
Autoantibodies 68 (68) 7 (7) 0.0001 137 (51) 15 (11) 0.0001
Anticentromere antibody 33 (33) 5 (5) 0.0001 41 (15) 8 (6) 0.0057
Anti–topoisomerase I 34 (34) 1 (1) 0.0001 69 (26) 7 (5) 0.0001
Anti–RNA polymerase III 2 (2) 1 (1) 1.0 27 (10) 0 0.0001
Puffy fingers 61 (61) 17 (17) 0.0001 169 (63) 24 (18) 0.0001
Abnormal nailfold capillaries 54 (54) 24 (24) 0.0001 146 (54) 51 (37) 0.0010
Dilated vessels 37 (37) 28 (28) 0.08 124 (46) 34 (25) 0.0080
Avascular areas 21 (21) 11 (11) 0.08 86 (32) 9 (7) 0.0001
Hemorrhages 12 (12) 9 (9) 0.64 63 (24) 8 (6) 0.0001
Digital tip ulcers 53 (53) 8 (8) 0.0001 108 (40) 12 (9) 0.0001
Pitting scars 53 (53) 5 (5) 0.0001 105 (39) 5 (4) 0.0001
PAH or ILD 48 (48) 14 (14) 0.0001 138 (52) 14 (10) 0.0001
PAH 44 (44) 10 (10) 0.0001 20 (7) 2 (1) 0.012
ILD 12 (12) 4 (4) 0.037 131 (49) 12 (9) 0.0001
Telangiectasia 35 (35) 10 (10) 0.0001 68 (25) 13 (9) 0.0002
Skin thickening of fingers proximal to MCP joints 26 (26) 1 (1) 0.0001 105 (39) 6 (4) 0.0001
Skin thickening of fingers distal to MCP joints 5 (5) 38 (38) 0.0001 178 (66) 24 (18) 0.0001
* Data were prospectively collected on 605 consecutive patients with systemic sclerosis (SSc) or a scleroderma-like disorder (see Methods); half of
the SSc patients at each site were to have early SSc. A random sample of 100 SSc cases and 100 controls, 50% from North America and 50% from
Europe, was selected to form the derivation sample, and the remaining patients formed the validation sample. Except where indicated otherwise,
values are the number (%). IQR  interquartile range; PAH  pulmonary arterial hypertension; ILD  interstitial lung disease; MCP 
metacarpophalangeal.
† Listed in order of frequency of occurrence in the SSc derivation sample.
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maintaining sensitivity and specificity in the derivation
sample. The items deleted were finger flexion contrac-
tures, calcinosis, tendon or bursal friction rubs, renal
crisis, and esophageal dilation. Puffy fingers and sclero-
dactyly were combined into one item, and pulmonary
arterial hypertension and interstitial lung disease were
also combined into one item, resulting in 7 items for the
scoring system. In the derivation sample, with reduction
of the 14 items to 7, the sensitivity and specificity were
0.93 and 0.94, respectively. Weights were simplified by
dividing each weight by 5 and rounding to the nearest
integer. The threshold for this simplified scoring system
was determined to be 9. The resulting sensitivity and
specificity were 0.97 and 0.88, respectively.
Weights were further adjusted to align the scor-
ing system with the experts’ opinions (SSc or not SSc) on
each of the 38 difficult-to-classify cases. To improve the
specificity of the classification criteria, an exclusionary
criterion was added: patients with a diagnosis that better
explains their manifestations should not be classified as
having SSc. These revisions resulted in the correct
classification of all patient profiles judged to have SSc by
the majority of experts.
The SSc classification criteria. The new classifi-
cation criteria are presented in Table 1. The table shows
the 1 criterion that, if present, is sufficient for classifica-
tion as SSc, the 2 exclusionary criteria, and the 7 items
with a combined threshold above which cases are clas-
sified as SSc. The classification criteria may be applied
to patients who may have SSc and are being considered
for inclusion in an SSc study. As noted above, they are
not to be applied to patients who have a scleroderma-like
disorder that better explains their manifestations; and
patients with “skin thickening sparing the fingers” are not
classified as having SSc.
If a patient has skin thickening of the fingers
of both hands that extends proximal to the metacarpo-
phalangeal joints, the classification system assigns 9
points for this one item alone, which is sufficient to
classify the patient as having SSc with no further appli-
cation of the point system needed. Otherwise, the point
system is applied by adding the scores for manifestations
that are “positive.” The items are skin thickening of the
fingers, fingertip lesions, telangiectasia, abnormal nail-
fold capillaries, pulmonary arterial hypertension and/or
interstitial lung disease, Raynaud’s phenomenon, and
SSc-related autoantibodies. Two items, skin thickening
of the fingers and fingertip lesions, include 2 different
possible manifestations. If a patient has both manifesta-
tions, the score for the category is the higher score of the
2 manifestations. For example, in the item skin thicken-
ing of the fingers, if a patient has both manifestations,
i.e., puffy fingers (weighted 2) and sclerodactyly
(weighted 4), the total score for the item would be 4. The
maximum possible score is 19, and patients with a score
of 9 are classified as having SSc. The definitions of the
items used in the criteria are provided in Table 2.
Validation. Table 3 shows the characteristics of
the validation sample (268 patients with SSc, 137 con-
trols). The sensitivity and specificity of the new SSc
classification criteria were compared with those of the
1980 ACR classification criteria and the classification
criteria proposed by LeRoy and Medsger, and the results
are shown in Table 4. The sensitivity and specificity of
the new SSc criteria were, respectively, 0.91 and 0.92 in
the validation sample. The new criteria performed better
than the 2 earlier classification schemes in terms of
sensitivity and specificity (P 0.01 versus the 1980 ACR
criteria, P  0.004 versus the LeRoy/Medsger criteria).
The area under the receiver operating characteristic
curve of the classification system tested against presence
of SSc in the validation sample was 0.81 (95% confi-
dence interval 0.77–0.85). The performance of the new
criteria in patients with disease of 3 years’ duration
Table 4. Sensitivity and specificity of the 2013 SSc classification criteria and previous SSc classification criteria, overall and in early SSc*
Derivation sample
(n  200)
Validation sample
(n  405)
Validation sample, disease duration
3 years (n  100)
Sensitivity
(95% CI)
Specificity
(95% CI)
Sensitivity
(95% CI)
Specificity
(95% CI)
Sensitivity
(95% CI)
Specificity
(95% CI)
1980 ACR SSc criteria 0.80 (0.72–0.87) 0.77 (0.68–0.84) 0.75 (0.70–0.80) 0.72 (0.64–0.79) 0.75 (0.70–0.80) 0.72 (0.63–0.79)
2001 LeRoy/Medsger
SSc criteria
0.76 (0.68–0.84) 0.69 (0.68–0.84) 0.75 (0.70–0.80) 0.78 (0.70–0.85) 0.80 (0.69–0.88) 0.76 (0.53–0.92)
2013 ACR/EULAR
SSc criteria
0.95 (0.90–0.98) 0.93 (0.86–0.97) 0.91 (0.87–0.94) 0.92 (0.86–0.96) 0.91 (0.83–0.96) 0.90 (0.70–0.99)
* SSc  systemic sclerosis; 95% CI  95% confidence interval; ACR  American College of Rheumatology; EULAR  European League Against
Rheumatism.
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was similar to the performance in the group overall
(Table 4).
The classification system was additionally tested
against expert opinion (n  16 experts), using the set of
38 selected cases (Table 5). All of the cases scoring 9
were considered SSc, whereas cases scoring 9 were
regarded as not being SSc or were controversial. With
the proposed system all of these cases were classified in
accordance with consensus-based expert opinion. All cases
that were classified as SSc with the 1980 ACR criteria were
also classified as SSc with the new criteria, as were several
cases not classified as SSc with the 1980 ACR criteria.
Discussion
A classification system for systemic sclerosis is
needed to ensure that all patients categorized as having
SSc for inclusion in studies do indeed have the disease,
based on specific defined characteristics. The major
reason to revise the 1980 ACR criteria was that those
criteria lacked adequate sensitivity, especially in patients
with early SSc or with limited cutaneous SSc (9,10,18).
The proposed classification criteria are superior and
exhibit greater sensitivity and specificity compared to
the 1980 criteria and the classification criteria proposed
Table 5. Expert consensus versus classification systems for selected case profiles*
No.
Skin
thickening of
the fingers Fingertips Telangiectasia
Abnormal
nailfold
capillaries
Puffy
fingers
Raynaud’s
phenomenon
ILD/
pulmonary
fibrosis PAH
SSc-related
autoantibodies
Classified
as SSc Score
1980
ACR
criteria
fulfilled
No. of
experts
agreeing
(n  16)
1 Whole finger Pitting scars – Yes Yes Yes – Yes Yes Yes 17 Yes 16
2 Whole finger Pitting scars – – Yes Yes Yes – Yes Yes 15 Yes 16
3 Whole finger Pitting scars – – Yes Yes – – Yes Yes 13 Yes 16
4 Whole finger Pitting scars Yes Yes – Yes – – – Yes 12 Yes 15
5 Whole finger – – Yes Yes Yes – – Yes Yes 12 No 15
6 Whole finger – – Yes – Yes – – – Yes 11 No 10
7 – Pitting scars – – Yes Yes Yes – – Yes 10 ? NA
8 – Ulcers – – – Yes Yes – Yes Yes 10 No 14
9 – – – Yes – Yes Yes – Yes Yes 10 No NA
10 – – – Yes Yes Yes – – Yes Yes 10 No NA
11 – Ulcers – – Yes Yes – – Yes Yes 10 No NA
12 – – – Yes Yes Yes – – Yes Yes 10 No NA
13 Whole finger – – – Yes Yes – – Yes Yes 10 No 15
14 Whole finger – – – – Yes – – Yes Yes 10 No NA
15 Whole finger – – Yes – Yes – – – Yes 9 No NA
16 Whole finger – Yes – Yes Yes – – – Yes 9 No NA
17 Whole finger Ulcers – – Yes Yes – – – Yes 9 No NA
18 Whole finger – – Yes – Yes – – – Yes 9 No NA
19 Whole finger – – Yes Yes Yes – – – Yes 9 No 9
20 Whole finger – – Yes – Yes – – – Yes 9 No NA
21 – Pitting scars – – – Yes Yes – – No 8 ? NA
22 – – – – Yes Yes – – Yes No 8 No NA
23 – Pitting scars – Yes – Yes – – – No 8 No 4
24 – Pitting scars Yes – – Yes – – – No 8 No 2
25 – – – Yes – Yes – – Yes No 8 No NA
26 – – – – Yes Yes Yes – – No 7 No NA
27 – – – Yes Yes Yes – – – No 7 No NA
28 Distal to PIP
joints
– – Yes Yes Yes – – – No 7 No 5
29 – – – Yes – Yes Yes – – No 7 No NA
30 Whole finger – – – – Yes – – – No 7 No NA
31 Whole finger – Yes – Yes – – – – No 6 No NA
32 Distal to PIP
joints
– – – – Yes – – Yes No 6 No 8
33 – – – – – Yes – – Yes No 6 No 0
34 – – – – – – Yes – Yes No 5 No NA
35 – – – – – Yes – Yes – No 5 No 0
36 – – – Yes – Yes – – – No 5 No 1
37 – – – Yes – – – – Yes No 5 No 0
38 – – – Yes – – – – – No 2 No 0
* Profiles of 38 cases with likely systemic sclerosis (SSc) or an SSc-like disorder, with presence or absence of the manifestations in the newly developed American College
of Rheumatology (ACR)/European League Against Rheumatism SSc classification criteria, are shown. The cases are listed in order of the points awarded using the
classification system (Score column) and are classified as SSc if the score is 9. For 18 of the cases, the number of experts agreeing that the case had SSc is shown. None
of the cases had skin thickening of the fingers of both hands extending proximal to the metacarpophalangeal joints (the single criteria that, if present, immediately
classifies the individual as having SSc). Whole finger is sclerodactyly of the entire finger but not proximal to the metacarpophalangeal joints. ILD  interstitial lung
disease; PAH  pulmonary arterial hypertension; ?  inconclusive; NA  not applicable (experts were not asked); PIP  proximal interphalangeal.
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by LeRoy and Medsger. All profiles of patients who
were considered to have SSc by a majority of experts
were indeed classified as SSc with the new classification
system, and the new system is more inclusive and also
performs well in patients with early disease (3 years
since diagnosis).
The newly developed classification system in-
cludes disease manifestations of the 3 hallmarks of SSc:
fibrosis of the skin and/or internal organs, production of
certain autoantibodies, and vasculopathy. The 4 items
comprising the 1980 ACR classification criteria (sclero-
derma proximal to the metacarpophalangeal joints,
sclerodactyly, digital pitting scars [not pulp loss], and
bilateral basilar pulmonary fibrosis) (3) are also in-
cluded, as are the items in the criteria proposed in 2001
by LeRoy and Medsger (Raynaud’s phenomenon, auto-
antibodies, nailfold capillaroscopy abnormalities, skin
fibrosis) (6).
The new criteria include 1 criterion that alone is
sufficient for classification as SSc: skin thickening of the
fingers extending proximal to the metacarpophalangeal
joints, which is similar to the 1980 criteria. If the single
sufficient criterion is not fulfilled, the point system is
applied and patients with a score of 9 are classified as
having SSc. All items in the classification criteria repre-
sent measurements that are performed in routine clini-
cal practice. The criteria are meant for inclusion of SSc
patients in studies, not for SSc diagnosis. Although the
list of items in the classification criteria mimics the list
of items one usually uses for diagnosis, in practice the
diagnosis of SSc may also be informed by items not
included in the classification criteria, such as tendon
friction rubs, calcinosis, and dysphagia. Consequently,
patients classified as having SSc are a subset of patients
being diagnosed as having SSc, with diagnosis being more
sensitive. Ideally, there would be no difference between
diagnosis and classification criteria.
As intended, the new classification system incor-
porates the considerable advances made in the diagnosis
of SSc. It includes the concept of specific serum auto-
antibodies such as anti–topoisomerase I, anticentro-
mere, and anti–RNA polymerase III (15,23). There is
the possibility that testing for additional SSc autoanti-
bodies, such as anti-Th/To, anti–U3 RNP, and others,
may become more widely available. The criteria also
acknowledge the value of magnified nailfold visualiza-
tion in the diagnosis of SSc (14,15). Although capillaros-
copy can be performed with highly specialized equip-
ment such as videocapillaroscopy cameras, simple in-
office ophthalmoscopes or dermatoscopes suffice for
distinguishing between normal and abnormal nailfold
capillaries (24,25). Capillaroscopy is now widely used,
and considering the value of magnified nailfold visual-
ization in the diagnosis and management of SSc, these
new criteria may encourage acquisition of this skill by
physicians caring for SSc patients. Likewise, criteria for
pulmonary artery hypertension have changed over the
years. The ACR/EULAR committee recognizes this,
and the diagnosis of pulmonary artery hypertension
should be based on the most recent accepted criteria
from right-sided heart catheterization.
Several items that are useful for recognizing SSc
in clinical practice, such as calcinosis, flexion contrac-
tures of the fingers, tendon or bursal friction rubs, renal
crisis, esophageal dilatation, and dysphagia are not in-
cluded in the criteria. These were considered but did
not substantially improve sensitivity or specificity. For
example, renal crisis is a strong indicator of SSc, but its
low frequency of occurrence makes it less useful for the
purpose of classification (20). The committee consid-
ered a non–point-based additive system (8), such as the
ACR systemic lupus erythematosus criteria (26) or the
1980 ACR SSc criteria. We concluded, however, that
assigning weights yielded superior results for SSc classi-
fication. Indeed, the weights were simplified to single-
digit numbers to make the system easy to use even in the
absence of a computing device. Similar weighted systems
have been used for other rheumatic diseases (27). The
committee also decided not to include “probable” or
“possible” SSc in the classification.
Examples of profiles not captured by the 1980
ACR criteria that fulfilled the new classification criteria
are combinations of skin thickening of the whole finger,
SSc-related autoantibodies, and pulmonary arterial hy-
pertension and/or Raynaud’s phenomenon. A patient
with Raynaud’s phenomenon, autoantibodies, and ab-
normal nailfold capillaries is not classified as having SSc,
although such a patient may develop SSc over subse-
quent years (6,15).
Patients may have disease manifestations similar
to those of SSc that are better explained by another
well-defined disorder, such as nephrogenic sclerosing
fibrosis, generalized morphea, eosinophilic fasciitis,
scleredema diabeticorum, scleromyxedema, porphyria,
lichen sclerosis, graft-versus-host disease, or diabetic
cheiroarthropathy. We decided it was not necessary to
develop criteria that differentiated SSc specifically from
these conditions. Patients with some of these diseases
were included in the validation cohort of patients with
SSc-like disorders, and it is possible that specificity may
have been slightly higher had they been excluded.
In developing the revised SSc classification crite-
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ria, we followed the recommendations and guidelines of
the ACR and EULAR, which included 1) collaboration
between clinical experts and clinical epidemiologists in
criteria development, 2) evaluation of the psychometric
properties of each candidate criterion, and 3) descrip-
tion of the test sample (origin of the patients and control
subjects) (7,28). Ideally, phases of criteria development
should have a balance between expert opinion and
data-driven methods; yet, there should be avoidance of
circularity of reasoning (a bias that can occur when the
same experts developing the criteria are the ones con-
tributing cases and comparison patients) (29). We in-
cluded different experts at different steps in the devel-
opment of the SSc criteria, to avoid circularity.
Testing and validating a classification system for
SSc is difficult because there is no gold standard for
defining a particular case as SSc; that is, there is no
incontrovertible test or criterion. We relied on expert
opinion for our gold standard, which is similar to the
process used in the development of other criteria (8).
In the absence of a gold standard, we developed
and tested the proposed classification system against two
standards of expert opinion: 1) the opinion of the
clinician who selected cases for the North American and
European derivation and validation cohorts, and 2) the
combined opinion of a group of clinical experts in SSc.
Both standards have strengths and weaknesses. Each
individual clinician who selected cases had access to
information that could have included aspects not cap-
tured by the forms, which were restricted to 23 particular
manifestations. Data were obtained from several sites in
Europe and North America, so this should improve
generalizability and reduce selection bias. However, it is
possible that other expert clinicians may have had a
different opinion about particular cases. The consensus
opinion of a group of experts who had the opportunity to
discuss controversial cases strengthens the combined
expert opinion. However, the group may not have been
aware of some relevant information not included in the
available data. It is also difficult for a group of experts to
consider hundreds of cases in depth; however, this was
managed by having the group consider in depth only
those cases, or combinations of items, that appeared to
be controversial. In this way, the expert group was able
to form a consensus over the whole range of cases in the
database. A key strength of the present work is the use
of both standards for testing and validation of the
proposed system.
The approach we used has other strengths and
limitations as well. The methodology was state of the art,
with validation by data and by expert opinion at every
step. Various methods used in the development process
have already been described (19,20). The criteria have
face validity, because the items are routinely assessed in
daily clinical practice and also were included in other
important SSc classification criteria sets. The criteria
allow for new developments in e.g., autoantibody testing
availability and/or new identification of scleroderma-
associated autoantibodies, or assessment of nailfold
capillaries. Formal conjoint analysis to derive the
weights associated with items improved the sensitivity
and specificity of the items, as was found also in the
development of the recent ACR/EULAR criteria for the
classification of rheumatoid arthritis (30).
The criteria have not been validated in ethnic
groups that are not common in North America and
Europe. This will require further studies. Regarding
clinical use, the number of items and weights may not be
easy to remember, but wide availability and (electronic)
applications can be developed. The SSc classification
criteria steering committee and the expert consultants
agreed that the criteria could allow for classification of
patients with another rheumatic disease as also having
SSc (e.g., having both systemic lupus erythematosus and
SSc, or rheumatoid arthritis and SSc, etc.). Although this
is a possible limitation, it permits individual researchers
to decide whether to include subjects who fulfill criteria
for more than one rheumatic disease in any particular
study.
Conclusions
The ACR/EULAR classification criteria for SSc
perform better than 1980 ACR preliminary criteria in
terms of both sensitivity and specificity. They are rela-
tively simple to apply to individual subjects. These
criteria may be endorsed as inclusion criteria for SSc
studies. Validation in other populations is encouraged.
AUTHOR CONTRIBUTIONS
All authors were involved in drafting the article or revising it
critically for important intellectual content, and all authors approved
the final version to be published. Drs. Van den Hoogen and Pope had
full access to all of the data in the study and take responsibility for the
integrity of the data and the accuracy of the data analysis.
Study conception and design. Van den Hoogen, Khanna, Fransen,
Johnson, Baron, Tyndall, Matucci-Cerinic, Naden, Riemekasten,
Denton, Furst, Gabrielli, Mayes, Seibold, Czirjak, Steen, Inanc,
Mu¨ller-Ladner, Veale, Walker, Chung, Herrick, Sierakowski, Silver,
Pope.
Acquisition of data. Van den Hoogen, Khanna, Johnson, Baron,
Tyndall, Matucci-Cerinic, Medsger, Carreira, Riemekasten, Clements,
Denton, Distler, Allanore, Furst, Mayes, Seibold, Czirjak, Steen,
Inanc, Kowal-Bielecka, Valentini, Veale, Vonk, Walker, Collier, Csuka,
2746 VAN DEN HOOGEN ET AL
Fessler, Guiducci, Hsu, Jimenez, Kahaleh, Merkel, Sierakowski, Silver,
Simms, Varga, Pope.
Analysis and interpretation of data. Van den Hoogen, Khanna,
Fransen, Johnson, Baron, Tyndall, Matucci-Cerinic, Naden, Medsger,
Riemekasten, Clements, Denton, Furst, Mayes, van Laar, Steen,
Inanc, Kowal-Bielecka, Valentini, Veale, Merkel, Sierakowski, Pope.
REFERENCES
1. Wollheim FA. Classification of systemic sclerosis: visions and
reality. Rheumatology (Oxford) 2005;44:1212–6.
2. Masi AT, Medsger TA Jr, Rodnan GP, Fries JF, Altman RD,
Brown BW, et al. Methods and preliminary results of the Sclero-
derma Criteria Cooperative Study of the American Rheumatism
Association. Clin Rheum Dis 1979;5:27–79.
3. Subcommittee for Scleroderma Criteria of the American Rheu-
matism Association Diagnostic and Therapeutic Criteria Commit-
tee. Preliminary criteria for the classification of systemic sclerosis
(scleroderma). Arthritis Rheum 1980;23:581–90.
4. Preliminary criteria for the classification of systemic sclerosis
(scleroderma). Bull Rheum Dis 1981;31:1–6.
5. Nadashkevich O, Davis P, Fritzler MJ. A proposal of criteria for
the classification of systemic sclerosis. Med Sci Monit 2004;10:
CR615–21.
6. LeRoy EC, Medsger TA Jr. Criteria for the classification of early
systemic sclerosis. J Rheumatol 2001;28:1573–6.
7. Classification and Response Criteria Subcommittee of the Amer-
ican College of Rheumatology Committee on Quality Measures.
Development of classification and response criteria for rheumatic
diseases [editorial]. Arthritis Rheum 2006;55:348–52.
8. Johnson SR, Goek ON, Singh-Grewal D, Vlad SC, Feldman BM,
Felson DT, et al. Classification criteria in rheumatic diseases: a
review of methodologic properties. Arthritis Rheum 2007;57:
1119–33.
9. Lonzetti LS, Joyal F, Raynauld JP, Roussin A, Goulet JR, Rich E,
et al. Updating the American College of Rheumatology prelimi-
nary classification criteria for systemic sclerosis: addition of severe
nailfold capillaroscopy abnormalities markedly increases the sen-
sitivity for limited scleroderma [letter]. Arthritis Rheum 2001;44:
735–6.
10. Hachulla E, Launay D. Diagnosis and classification of systemic
sclerosis. Clin Rev Allergy Immunol 2011;40:78–83.
11. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T,
Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classifica-
tion, subsets and pathogenesis. J Rheumatol 1988;15:202–5.
12. Avouac J, Fransen J, Walker UA, Riccieri V, Smith V, Muller C,
et al, EUSTAR Group. Preliminary criteria for the very early
diagnosis of systemic sclerosis: results of a Delphi consensus
study from EULAR Scleroderma Trials and Research Group. Ann
Rheum Dis 2011;70:476–81.
13. Walker JG, Pope J, Baron M, Leclercq S, Hudson M, Taillefer S,
et al. The development of systemic sclerosis classification criteria.
Clin Rheumatol 2007;26:1401–9.
14. Harper FE, Maricq HR, Turner RE, Lidman RW, LeRoy EC. A
prospective study of Raynaud phenomenon and early connective
tissue disease: a five-year report. Am J Med 1982;72:883–8.
15. Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M,
Boire G, et al. Autoantibodies and microvascular damage are
independent predictive factors for the progression of Raynaud’s
phenomenon to systemic sclerosis: a twenty-year prospective study
of 586 patients, with validation of proposed criteria for early
systemic sclerosis. Arthritis Rheum 2008;58:3902–12.
16. Maricq HR, Weinberger AB, LeRoy EC. Early detection of
scleroderma-spectrum disorders by in vivo capillary microscopy:
a prospective study of patients with Raynaud’s phenomenon.
J Rheumatol 1982;9:289–91.
17. Cutulo M, Matucci-Cerinic M. Nailfold capillaroscopy and classi-
fication criteria for systemic sclerosis. Clin Exp Rheumatol 2007;
25:663–5.
18. Hudson M, Taillefer S, Steele R, Dunne J, Johnson SR, Jones N,
et al. Improving the sensitivity of the American College of
Rheumatology classification criteria for systemic sclerosis. Clin
Exp Rheumatol 2007;25:754–7.
19. Fransen J, Johnson SR, van den Hoogen F, Baron M, Allanore Y,
Carreira PE, et al. Items for developing revised classification
criteria in systemic sclerosis: results of a consensus exercise.
Arthritis Care Res (Hoboken) 2012;64:351–7.
20. Johnson SR, Fransen J, Khanna D, Bacon M, van den Hoogen F,
Medsger TA Jr, et al. Validation of potential classification criteria
for systemic sclerosis. Arthritis Care Res (Hoboken) 2012;64:
358–67.
21. Hansen P, Ombler F. A new method for scoring multi-attribute
value models using pairwise rankings of alternatives. J Multi-Crit
Decis Anal 2009;15:87–107.
22. Johnson SR, Naden RP, Fransen J, van den Hoogen FH, Pope JE,
Baron M, et al. Systemic sclerosis classification criteria: developing
methods for multi-criteria decision analysis [abstract]. Arthritis
Rheum 2012;64 Suppl:S372.
23. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis
Rheum 2005;35:35–42.
24. Baron M, Bell M, Bookman A, Buchignani M, Dunne J, Hudson
M, et al. Office capillaroscopy in systemic sclerosis. Clin Rheuma-
tol 2007;26:1268–74.
25. Hudson M, Masetto A, Steele R, Arthurs E, Baron M, for the
Canadian Scleroderma Research Group. Reliability of widefield
capillary microscopy to measure nailfold capillary density in
systemic sclerosis. Clin Exp Rheumatol 2010;28:S36–41.
26. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield
NF, et al. The 1982 revised criteria for the classification of systemic
lupus erythematosus. Arthritis Rheum 1982;25:1271–7.
27. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham
CO III, et al. 2010 rheumatoid arthritis classification criteria: an
American College of Rheumatology/European League Against
Rheumatism collaborative initiative. Arthritis Rheum 2010;62:
2569–81.
28. Dougados M, Gossec L. Classification criteria for rheumatic dis-
eases: why and how? [editorial]. Arthritis Rheum 2007;57:1112–5.
29. Felson DT, Anderson JJ. Methodological and statistical ap-
proaches to criteria development in rheumatic diseases. Baillieres
Clin Rheumatol 1995;9:253–66.
30. Neogi T, Aletaha D, Silman AJ, Naden RL, Felson DT, Aggarwal
R, et al. The 2010 American College of Rheumatology/European
League Against Rheumatism classification criteria for rheumatoid
arthritis: Phase 2 methodological report. Arthritis Rheum 2010;
62:2582–91.
ACR/EULAR CLASSIFICATION CRITERIA FOR SSc 2747
